Dashboard
Manage Tickers

STOK


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

canaccord-genuity-maintains-buy-on-stoke-therapeutics-raises-price-target-to-28
Canaccord Genuity Maintains Buy on Stoke T...
11/05/2025 18:31:28

Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target ...

wedbush-maintains-outperform-on-stoke-therapeutics-raises-price-target-to-32
Wedbush Maintains Outperform on Stoke Ther...
11/05/2025 14:23:27

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $2...

6-analysts-have-this-to-say-about-stoke-therapeutics
6 Analysts Have This To Say About Stoke Th...
11/05/2025 11:45:33

btig-reiterates-buy-on-stoke-therapeutics-maintains-39-price-target
BTIG Reiterates Buy on Stoke Therapeutics,...
11/05/2025 10:15:05

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
11/04/2025 21:06:29

stoke-therapeutics-q3-eps-065-misses-059-estimate-sales-10632m-beat-5511m-estimate
Stoke Therapeutics Q3 EPS $(0.65) Misses $...
11/04/2025 21:02:41

Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of ...

earnings-scheduled-for-november-4-2025
Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

examining-the-future-stoke-therapeuticss-earnings-outlook
Examining the Future: Stoke Therapeutics's...
11/03/2025 20:02:44

jp-morgan-maintains-neutral-on-stoke-therapeutics-raises-price-target-to-25
JP Morgan Maintains Neutral on Stoke Thera...
11/03/2025 15:53:14

JP Morgan analyst Jessica Fye maintains Stoke Therapeutics (NASDAQ:STOK) with a Neutral and raises the price target from $15...

stoke-therapeutics-unveils-two-year-data-offering-hope-for-patients-with-rare-genetic-vision-disorder
Stoke Therapeutics Unveils Two-Year Data O...
10/20/2025 11:36:16

Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bod...

what-4-analyst-ratings-have-to-say-about-stoke-therapeutics
What 4 Analyst Ratings Have To Say About S...
10/10/2025 22:01:27

needham-maintains-buy-on-stoke-therapeutics-raises-price-target-to-35
Needham Maintains Buy on Stoke Therapeutic...
10/10/2025 10:22:26

Needham analyst Joseph Stringer maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $22 t...

Core News & Articles
Biogen And Stoke Announce Phase 3 Zorevune...
10/09/2025 20:32:46

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improveme...

stoke-therapeutics-names-ian-f-smith-ceo
Stoke Therapeutics Names Ian F. Smith CEO
10/06/2025 11:36:29

Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Exe...

Core News & Articles
Reported Earlier, Biogen And Stoke Highlig...
09/03/2025 06:55:31

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...

Core News & Articles
Reported Earlier: Biogen And Stoke Therape...
09/02/2025 13:56:46

– Durable reductions in seizures and continuing improvements in cognition and behavior through 3 years in patients who continue...

Core News & Articles
Biogen And Stoke Therapeutics Announced Pr...
08/25/2025 11:10:57

where-stoke-therapeutics-stands-with-analysts
Where Stoke Therapeutics Stands With Analysts
08/13/2025 20:01:40

chardan-capital-maintains-buy-on-stoke-therapeutics-maintains-24-price-target
Chardan Capital Maintains Buy on Stoke The...
08/13/2025 16:05:17

Chardan Capital analyst Rudy Li maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $24 price target.

wedbush-maintains-outperform-on-stoke-therapeutics-raises-price-target-to-22
Wedbush Maintains Outperform on Stoke Ther...
08/13/2025 14:30:48

Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION